Improving treatment outcomes by understanding cytogenetics in myelodysplastic syndromes

Haematologica Reports

Volumn 2, Issue 14, 2006, Pages 5-10

  Giagounidis, Aristotle ^a  

^a ST JOHANNES HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CYTARABINE; DANAZOL; ERYTHROPOIETIN; LENALIDOMIDE; PYRIDOXINE; RETINOIC ACID; STEROID;

ALLOGENEIC STEM CELL TRANSPLANTATION; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION 5; CONFERENCE PAPER; CYTOGENETICS; DISEASE CLASSIFICATION; HUMAN; MYELODYSPLASTIC SYNDROME; PROGNOSIS; SURVIVAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 33846303231     PISSN: 18249337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-99.
2. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms Blood 2002;100:2292-302.
3. Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-603.
4. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
5. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Invernizzi R, Giagounidis A, et al. A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes [abstract 788]. Blood 2005;106:232a-3a
6. Haase D, Steidl C, Schanz J, Schabla R, Pfeilstocker M, Nosslinger T, et al. Correlation of cytogenetic findings with morphology, clinical course and prognosis in 2124 patients with MDS [abstract 787]. Blood 2005;106;232a.
7. Boultwood J, Fidler C, Strickson AJ, Watkins F, Kostrzewa M, Jaju RJ, et al. Transcription mapping of the 5q- syndrome critical region: cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs. Genomics 2000;66:26-34.
8. Horrigan SK, Arbieva ZH, Xie HY, Kravarusic J, Fulton NC, Naik H, et al. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood 2000;95:2372-7.
9. Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C. The 5q- syndrome. Hematology 2004;9:271-7.
10. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004;18:113-9.
11. Giagounidis AA, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 2005;84:569-71.
12. Sole F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luno E, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperative Espanol de Citogenetica Hematologica. Br J Haematol 2000;108:346-56.
13. Hackanson B, Robbel C, Wijermans P, Lübbert M. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies. Ann Hematol 2005;84 Suppl 13:32-8.
14. Raj KK, John AM, Ho A, Thomas NSB, Mufti GJ. Early and sustained response to azacytidine in high-risk MDS patients with monosomy 7 correlates with increased apoptosis and not CDKN2B demethylation [abstract 2530]. Blood 2005;106:710a-711a.
15. Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Busche G, et al. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study. Ann Hematol 2005;84:389-94.
16. Giagounidis AAN, Haase S, Germing U, Hildebrandt B, Heinsch M, Aivado M, et al. Low-dose cytarabine in the treatment of patients with the 5q- syndrome. Onkologie 2002;25:66.
17. Juneja HS, Jodhani M, Gardner FH, Trevarthen D, Schottstedt M. Low-dose ARA-C consistently induces hematologic responses in the clinical 5q- syndrome. Am J Hematol 1994;46:338-42.
18. Stewart B, Verdugo M, Guthrie KA, Appelbaum F, Deeg HJ. Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes. Br J Haematol 2003;123:879-85.
19. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiDs® derivatives as anticancer agents. Nat Rev Cancer 2004;4:314-22.
20. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-57.
21. List AF, Dewald J, Bennett J, Giagounidis AA, Raza A, Feldman E, et al. Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study [abstract 5]. J Clin Oncol 2005;23:2s.
22. + hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 2002;100;259-67.